CRISPR/Cas9 mediated CXCL4 knockout in human iPS cells of polycythemia vera patient with JAK2 V617F mutation.
The chemokine CXCL4/platelet factor 4 (PF4) gene, a key player in myelofibrosis, was knocked out by CRISPR/Cas9 in induced pluripotent stem cells (iPS cells) of a polycythemia vera (PV) patient with JAK2 V617F mutation. Two CXCL4KO iPS cell lines with and without JAK2 V617F mutation (UKAi002-B-1 and UKAi002-A-1, respectively) were generated. CXCL4KO iPS cells showed deletion of exon 1 and complete loss of CXCL4 protein. Pluripotency of iPS cells was confirmed by expression of pluripotency markers and trilineage differentiation. CXCL4KO iPS cells are expected to provide a valuable tool for investigating the role of CXCL4 in human diseases.
['Boehnke|Janik|J|', 'Atakhanov|Salim|S|', 'Toledo|Marcelo A S|MAS|', 'Schüler|Herdit M|HM|', 'Sontag|Stephanie|S|', 'Chatain|Nicolas|N|', 'Koschmieder|Steffen|S|', 'Brümmendorf|Tim H|TH|', 'Kramann|Rafael|R|', 'Zenke|Martin|M|']
D064113:CRISPR-Cas Systems D006801:Humans D057026:Induced Pluripotent Stem Cells D053614:Janus Kinase 2 D009154:Mutation D011087:Polycythemia Vera
CXCL4 iPS cells JAK2 V617F PF4 Induced pluripotent stem cell Hematopoiesis